SIETES :: 93212 citas

Resultados de la búsqueda por MECANISMO DE ACCIÓN REFINAR BÚSQUEDA

1.

Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2021;384:18 de febrero. [Ref.ID 103836]

2.

Aby ES, Rodin H, Debes JD. Proton pump inhibitors and mortality in individuals with COVID-19. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103830]

3.

Corbella J. La primera vacuna de la Covid ensayada en personas muestra eficacia. La Vanguardia 2020:19 de mayo. [Ref.ID 103619]

4.

Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020;369:8 de abril. [Ref.ID 103595]

5.

Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. A non–D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 2020;382:1497-506. [Ref.ID 103592]

6.

Wang Y-H, Wintzell V, Ludvigsson JF, Svanström H, Pasterenak B. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatrics 2020;174:junio. [Ref.ID 103566]

7.

Garcia P, Lafaurie M. Le priapisme, un effet indésirable des neuroleptiques à ne pas méconnaître. BIP Occitanie 2019;26:76. [Ref.ID 103241]

8.

Parsons L. Novartis acquires The Medicines Company for $9.7bn following takeover rumours. PMLiVE 2019:25 de noviembre. [Ref.ID 103211]

9.

Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]

10.

Conte C, Despas F. Le beau mois de Juin des inhibiteurs de protéines kinases. BIP Occitanie 2019;26:junio. [Ref.ID 103136]

11.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ 2019;365:4 de abril. [Ref.ID 103086]

12.

Taylor SN, Marrazzo J, Batteiger BE, Hook III EW, Seña AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, Mueller J. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med 2018;379:8 de noviembre. [Ref.ID 102865]

13.

Nguyen TTH, Roussin A, Rousseau A, Montastruc J-L, Montastruc F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: A pharmacoepidemiological–pharmacodynamic study in VigiBase®. Drug Saf 2018;41:noviembre. [Ref.ID 102840]

14.

Floyd CN, Warren JB. Opioids out of control. Br J Clin Pharmacol 2018;84:mayo. [Ref.ID 102794]

15.

Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]

16.

Anónimo. Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis. ISMP Quarter Watch 2018:6. [Ref.ID 102509]

17.

Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]

18.

Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]

19.

Öngür D. Dopamine dysfunction in schizophrenia and bipolar disorder - Never the twain shall meet?. JAMA Psychiatry 2017:11 de octubre. [Ref.ID 102090]

20.

Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, Turkheimer F, McGuire P, Young AH, Howes OD. A tests of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 2017:11 de octubre. [Ref.ID 102089]